Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- Differential diagnosis begins with deciding when a nonspecific phenotype is suspicious enough to justify an amyloidosis workup.
- Suspicion usually rests on a cluster of cardiac and extracardiac clues rather than a single finding.
- Excluding AL amyloidosis is the key early branch point because it changes how imaging results can be interpreted.
- Echocardiography, cardiac MRI, and bone-avid scintigraphy can help refine diagnosis of ATTR-CM within the context of the broader clinical picture.
When a Nonspecific Phenotype Warrants an Amyloidosis Workup
The differential diagnosis of ATTR-CM is challenging because its clinical phenotype is plausible but not specific. Findings may include increased left ventricular wall thickness, heart-failure symptoms, conduction disease, restrictive physiology, or a mixed pattern that overlaps with more common cardiomyopathies. The practical task is deciding when that pattern is coherent enough to justify a structured amyloidosis workup rather than routine cardiomyopathy follow-up alone. This same threshold guides screening and early detection.
How Clustering Raises Suspicion
Clinical suspicion strengthens through clustering rather than any single finding. Left ventricular wall thickening disproportionate to ECG voltage, restrictive filling, atrial arrhythmias, conduction disease, carpal tunnel syndrome, spinal stenosis, neuropathy, or autonomic features can each make ATTR-CM more plausible, but none is individually diagnostic. The key differential is AL amyloidosis, not another cardiomyopathy, because it can present with similar clinical features and imaging findings while altering both prognosis and the diagnostic pathway.
Why Monoclonal Testing Is the Pivotal Branch Point
Monoclonal protein assessment is the key component of the diagnostic algorithm that determines how subsequent imaging results are interpreted. Serum free light chain testing together with serum and urine immunofixation electrophoresis determine whether an imaging-led ATTR pathway remains appropriate or whether AL amyloidosis must stay in active consideration. When monoclonal studies are normal and the phenotype fits, a positive bone-avid scan strengthens the case for ATTR. When they are abnormal, however, the same scan cannot be interpreted in isolation, and tissue typing becomes important. That dependency is the core of excluding AL and reading the phenotype.
How Imaging Fits the Differential
Echocardiography, cardiac MRI, and 99mTc-PYP scintigraphy refine probability of ATTR but are most useful within the broader clinical picture rather than as isolated answers. Each can raise or lower suspicion, but their interpretation depends on phenotype and monoclonal status, which is why 99mTc-PYP scintigraphy is read as one concordant step in a sequence and should not be interpreted in isolation.
Practical Branch-Point Checklist
Before treating ATTR-CM as the working diagnosis, confirm the logic:
- Does a cluster of cardiac and extracardiac clues as opposed to a single finding support suspicion?
- Have serum free light chains plus serum and urine immunofixation electrophoresis been done to screen for AL?
- Are imaging findings being interpreted in light of monoclonal status rather than alone?
- If monoclonal studies are abnormal or the findings are discordant, has tissue typing or specialist referral been considered?
Frequently Asked Questions
What usually makes ATTR-CM suspicious enough to enter the differential?
A compatible phenotype supported by clustered cardiac and extracardiac clues is usually more informative than any single isolated finding, and it’s what justifies moving to a structured amyloidosis workup.
Why is AL amyloidosis the key early exclusion?
AL amyloidosis can mimic ATTR-CM clinically and on imaging while changing both prognosis and how confidently an imaging-based nonbiopsy pathway can be used, so it must be addressed before ATTR-CM is treated as established.
How should imaging be used in the differential?
Imaging should refine suspicion and probability, not replace the broader workup that includes phenotype recognition and monoclonal testing; its weight depends on whether AL has been excluded.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.